GLP-1 Medications vs.
DPP-4 Inhibitors: How They Differ

The two groups meet the incretin system differently

Incretins are gut hormones that help regulate blood glucose after meals. Semaglutide is a GLP-1 receptor agonist. Its FDA label says it stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, and it delays early post-meal gastric emptying. In contrast, sitagliptin and saxagliptin are DPP-4 inhibitors. By blocking DPP-4, they prolong endogenous incretin activity rather than directly activating the GLP-1 receptor.^{[2] [5] [6]}

Tirzepatide needs a separate label. It is often discussed with GLP-1–based medicines, but it is not a GLP-1 receptor agonist alone. The Zepbound label identifies tirzepatide as a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist. It should not be described as proof that every GLP-1 receptor agonist has the same mechanism, indication, or result.^[4]

Type 2 diabetes overlaps, but product labels do not

Ozempic is a semaglutide injection approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. Its label also has specific cardiovascular and kidney risk-reduction indications in defined adult populations. Januvia and saxagliptin labels identify each as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; neither is for type 1 diabetes, and the saxagliptin label also says it is not recommended for diabetic ketoacidosis.^{[2] [5] [6]}

Product-specific obesity indications are different from glucose-lowering use. Wegovy is a semaglutide GLP-1 receptor agonist with a long-term weight-reduction and maintenance indication for defined people with obesity or overweight plus a weight-related condition. Zepbound is tirzepatide, the dual GIP/GLP-1 agonist, with its own chronic weight-management indication and a separate obstructive-sleep-apnea indication for adults with obesity. A diabetes product’s weight change in a trial does not create an obesity indication, and DPP-4 products reviewed here are diabetes-only labels.^{[3] [4] [5] [6]}

Head-to-head evidence favors larger average A1C and weight changes with GLP-1 receptor agonists

One 30-week, double-blind randomized study assigned 868 adults with type 2 diabetes inadequately controlled on metformin to weekly semaglutide 0.5 mg, semaglutide 1.0 mg, or daily sitagliptin 100 mg. Both studied semaglutide doses were superior to sitagliptin for the study’s A1C and body-weight endpoints. Gastrointestinal adverse events, including those leading to discontinuation, were more frequent with semaglutide.^[7]

A 2014 meta-analysis included four head-to-head randomized trials involving 1,755 participants. GLP-1 analogues reduced average A1C more than sitagliptin (mean difference −0.41 percentage points). The weight analysis, which used three of those trials, found an additional average reduction of 1.55 kg. It also found more gastrointestinal adverse events with GLP-1 analogues and a similar incidence of hypoglycemia. These results combine earlier studied drugs, doses, background therapy, and follow-up periods. They do not establish a universal ranking for newer products, guarantee an outcome, or outweigh a contraindication or tolerability issue.^[8]

Route is a practical difference, not a measure of treatment quality

The reviewed Ozempic label describes a once-weekly injection under the skin. The reviewed Januvia and saxagliptin labels describe oral tablets taken once daily. Semaglutide exists in other labeled formulations, so it is inaccurate to say every GLP-1 receptor agonist is an injection or to select a route from a class name alone.^{[2] [3] [5] [6]}

Route can shape questions about training, device or tablet instructions, stomach effects, other medicines, access, and follow-up. It does not settle clinical suitability. ADA recommends a shared-decision approach that considers glucose goals, cardiovascular, kidney, weight, and other conditions; hypoglycemia risk; adverse effects and tolerability; cost and access; and preferences.^[1]

Safety review must remain product-specific

For the reviewed semaglutide and tirzepatide products, a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and serious hypersensitivity are contraindication questions in the relevant labels. Those labels also address acute pancreatitis, gallbladder disease, severe gastrointestinal reactions, volume-depletion-related kidney injury, and low-glucose risk when combined with insulin or an insulin secretagogue. Ozempic specifically addresses diabetic-retinopathy complications, and its delayed gastric emptying can matter for oral medicines.^{[2] [3] [4]}

DPP-4 safety questions differ. Januvia’s label addresses postmarketing pancreatitis, hypersensitivity, renal-function assessment, severe joint pain, and bullous pemphigoid. It notes that heart failure has been observed with two other DPP-4 inhibitors and directs consideration of risks and benefits for people with heart-failure risk factors. The current saxagliptin label specifically says to consider heart-failure risks and benefits and monitor people with known risk factors. That is an agent-specific saxagliptin warning, not a claim that every DPP-4 inhibitor causes heart failure.^{[5] [6]}

Low-glucose risk changes with combinations

Incretin-pathway medicines do not eliminate the need to assess hypoglycemia. The Ozempic, Januvia, saxagliptin, and Zepbound labels each describe increased low-glucose risk when used with insulin or an insulin secretagogue, such as a sulfonylurea; the labels indicate that a lower dose of the concomitant insulin or secretagogue may be needed. This is a reason for prescriber and pharmacist review of the full regimen, not an instruction to change a dose independently.^{[2] [4] [5] [6]}

ADA also says that using a DPP-4 inhibitor together with a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist is not recommended because it does not add glucose lowering beyond GLP-1–based therapy. A clinician should assess the named product, other medicines, kidney function, relevant conditions, adverse effects, and access before starting, stopping, combining, or switching treatment.^[1]

Approved finished products and compounded preparations are not the same evidence category

The labels and trials discussed here concern FDA-approved finished products. FDA says compounded GLP-1 drugs are not FDA approved and do not undergo FDA review for safety, effectiveness, or quality before marketing. FDA says compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug. Branded semaglutide or tirzepatide data do not establish a compounded preparation’s quality, bioequivalence, safety, effectiveness, or outcomes.^[9]

For related educational reading, see what semaglutide is, GLP-1 medications versus SGLT2 inhibitors, and Luma’s treatment information.

Frequently asked questions